Epigenetic protein complexes: the adequate candidates for the use of a new generation of epidrugs in personalized and precision medicine in cancer.
Epigenomics
; 12(2): 171-177, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31849240
ABSTRACT
Until recently, drug development in oncology was focused on treating most patients for a specific cancer type without taking in account the heterogeneity between these patients in term of response to treatment. Therefore, this type of broad treatment approach excludes the treatment of patient not responding to disease-specific common drugs. In this review, we focus on the different types of epigenetic drugs currently used as DNA methylation inhibitor agents and their limits in patient care due to their lack of specificity. We also highlight the emergence of a new type of epidrug with higher target specificity due to their original mechanism of action the disruption of protein complexes involved in the epigenetic modifications.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Epigênese Genética
/
Medicina de Precisão
/
Neoplasias
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article